The substantial demand for collagenase clostridium histolyticum enzyme as a potential nonsurgical prescription treatment option for Dupuytren’s contracture condition and Peyronie’s disease. A number of approvals by prominent regional regulators, such as the U.S. FDA and the European Commission, in recent years is a noteworthy factor catalyzing the growth of the global collagenase clostridium histolyticum market. To shed light on such trends and key factors influencing the current market trajectory and emerging dynamics, Transparency Market Research (TMR) has penned a comprehensive report, titled “Collagenase Clostridium Histolyticum Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016–2024”.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4474
The collagenase clostridium histolyticum market is witnessing a sustained impetus from the rising prevalence of Dupuytren’s contracture in adult populations in several developed nations, notably the U.S. and the U.K. The emerging potential of the enzyme in the medical sector in applications such as wound care, necrosis treatment, burn and pain management, will also contribute to the rapid expansion of the market. The rising number of application in the healthcare sector is expected to accentuate the market’s growth.
In recent years, burgeoning clinical studies related to pharmacology and efficacy of collagenase clostridium histolyticum enzyme, especially in developed countries, is a notable trend providing a robust boost to the market. The rising number of additional trials for potential use of Xiaflex, approved by the U.S. FDA in the treatment of Dupuytren’s contracture in adult patients, is a notable factor adding to the attractiveness of the market. However, a number of serious side effects being reported in the recent years, especially related with the intake of Xiaflex, coupled with stringent regulations are crucial factors likely to restrain the development of the market.
Nevertheless, the marked lack of effective treatments for Dupuytren’s contracture and Peyronie’s disease has unlocked promising avenues in the market. Regionally, North America stands as a potential market for collagenase clostridium histolyticum, driven by the elevated awareness of these diseases and the rising number of pertinent clinical trials.
A number of pharmaceutical companies are focusing on mergers and acquisitions and collaborations to consolidate their shares. Prominent players operating in the collagenase clostridium histolyticum market include Swedish Orphan Biovitrum AB, Advanced Biofactures Corporation, Smith & Nephew Plc., Actelion Pharmaceuticals Canada Inc, Auxilium Pharmaceuticals Inc., BioSpecifics Technologies Corp., and Healthpoint Ltd.